source Post navigation Global Diabetes Drug Analysis Report 2024: A $107.02 Billion Market by 2032 Driven by Novo Nordisk, AstraZeneca … – GlobeNewswire Study Reveals Robust Benefits of Semaglutide in Protecting Against Kidney, CV Events in Patients With T2D – Drug Topics